Helle Linnebjerg
Research Subjects
Helle Linnebjerg has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Eric Chen Quin Lam
Formerly of Lilly-NUS Centre for Clinical Pharmacology, Singapore, Singapore
6 shared publications- Jennifer Leohr
Eli Lilly and Company Indianapolis Indiana USA
6 shared publications David Coutant
Eli Lilly and Company, Indianapolis, USA
4 shared publicationsDavid E. Coutant
Eli Lilly and Company, Lilly Corporate Center Indianapolis Indiana USA
3 shared publicationsElizabeth LaBell
Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
3 shared publicationsLaiyi Chua
Lilly-NUS Centre for Clinical Pharmacology, Singapore, Singapore
3 shared publications
Latest Publications
- Open Access
- 23 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4010-4018
Characterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes
Aims: To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods: This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years; HbA1c, 7.1 ± 0.64%; BMI, 31.7 ± 3.20 kg/m 2 ). Following a dose‐finding lead‐in period with once‐daily degludec, eligible participants received a one‐time loading dose of 12 U/kg efsitora followed by 9 weekly doses of 4 U/kg. Three 24‐h clamps were conducted on Days 1, 4, and 7 after the last efsitora dose. Model‐based interpolation was used to derive the glucodynamic profile over the weekly dosing interval at steady‐state. Results: Model‐predicted pharmacokinetic steady‐state was achieved between the 4th and 6th weekly dose of efsitora when using a one‐time loading dose. At steady‐state, the PK profile over the week had a low peak‐to‐trough ratio of 1.16, with a half‐life of 19 days. The model‐predicted glucose infusion rate profile, over the weekly dosing interval, demonstrated a stable glucose‐lowering effect of efsitora. The maximum glucose infusion rate occurred between Days 4 and 5. Efsitora showed an even distribution of the glucose‐lowering effect within a weekly dosing interval, with a peak‐to‐trough ratio of 1.07. Efsitora was safe and well tolerated. Conclusions: Efsitora demonstrated a flat, prolonged PK profile, providing a consistent level of insulin exposure at steady‐state and resulting in a stable glucose‐lowering response across the weekly dosing interval.
- 23 February 2026
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 28 (5) , 4010-4018
Open AccessCharacterisation of steady‐state pharmacokinetics and glucodynamics of once‐weekly insulin efsitora alfa in individuals with type 2 diabetes
Aims: To evaluate the steady‐state pharmacokinetics (PK) and glucodynamic effects of insulin efsitora alfa (efsitora) over a weekly interval in adults with type 2 diabetes (T2D). Materials and Methods: This open‐label, multiple dose, euglycaemic clamp study was conducted in 56 insulin naïve adults with T2D (mean [±SD] age, 61.9 ± 5.98 years; HbA1c, 7.1 ± 0.64%; BMI, 31.7 ± 3.20 kg/m 2 ). Following a dose‐finding lead‐in period with once‐daily degludec, eligible participants received a one‐time loading dose of 12 U/kg efsitora followed by 9 weekly doses of 4 U/kg. Three 24‐h clamps were conducted on Days 1, 4, and 7 after the last efsitora dose. Model‐based interpolation was used to derive the glucodynamic profile over the weekly dosing interval at steady‐state. Results: Model‐predicted pharmacokinetic steady‐state was achieved between the 4th and 6th weekly dose of efsitora when using a one‐time loading dose. At steady‐state, the PK profile over the week had a low peak‐to‐trough ratio of 1.16, with a half‐life of 19 days. The model‐predicted glucose infusion rate profile, over the weekly dosing interval, demonstrated a stable glucose‐lowering effect of efsitora. The maximum glucose infusion rate occurred between Days 4 and 5. Efsitora showed an even distribution of the glucose‐lowering effect within a weekly dosing interval, with a peak‐to‐trough ratio of 1.07. Efsitora was safe and well tolerated. Conclusions: Efsitora demonstrated a flat, prolonged PK profile, providing a consistent level of insulin exposure at steady‐state and resulting in a stable glucose‐lowering response across the weekly dosing interval.
- Open Access
- 3 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1964-1972
Ultra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus
Aim: This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6‐11 years), adolescents (12‐17 years) and adults (18‐64 years) with type 1 diabetes mellitus (T1D). Materials and Methods: The study was a randomized, two‐period, subject‐ and investigator‐blind, crossover design in participants with T1D. Participants received a 0.2 U/kg bolus dose immediately before a liquid mixed meal tolerance test. Insulin lispro and glucose concentrations were measured. Results: The study included 13 children, 14 adolescents and 15 adults. Consistently across the age groups, onset of appearance was 4‐5 min faster, the early 50% t max was reduced by 7‐13 min, and exposure in the first 15 min was increased by 3.5‐6.5‐fold following URLi compared with Humalog (all p < .01). Exposure after 3 h was decreased by 37‐58% ( p = .02) and the duration was reduced by 56 min ( p = .006) in children and 36 min ( p = .022) in adolescents with URLi compared with Humalog. The maximum and overall exposure were similar between treatments. Postprandial glucose at 1 h was reduced by 42 mg/dl in children ( p = .008), 19 mg/dl ( p = .195) in adolescents and 34 mg/dl ( p = .018) in adults following URLi versus Humalog. The glucose excursion during a 5‐h test meal period was reduced by 16% in children and 9% in adolescents compared with Humalog. URLi was well tolerated in all age groups. Conclusions: URLi showed an accelerated insulin lispro absorption and greater postprandial glucose reduction compared with Humalog in children, adolescents and adults with T1D.
- 3 May 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 25 (7) , 1964-1972
Open AccessUltra rapid lispro showed greater reduction in postprandial glucose versus Humalog in children, adolescents and adults with type 1 diabetes mellitus
Aim: This study compared the pharmacokinetics, glucodynamics and tolerability following single subcutaneous doses of ultra rapid lispro (URLi) versus Humalog in children (6‐11 years), adolescents (12‐17 years) and adults (18‐64 years) with type 1 diabetes mellitus (T1D). Materials and Methods: The study was a randomized, two‐period, subject‐ and investigator‐blind, crossover design in participants with T1D. Participants received a 0.2 U/kg bolus dose immediately before a liquid mixed meal tolerance test. Insulin lispro and glucose concentrations were measured. Results: The study included 13 children, 14 adolescents and 15 adults. Consistently across the age groups, onset of appearance was 4‐5 min faster, the early 50% t max was reduced by 7‐13 min, and exposure in the first 15 min was increased by 3.5‐6.5‐fold following URLi compared with Humalog (all p < .01). Exposure after 3 h was decreased by 37‐58% ( p = .02) and the duration was reduced by 56 min ( p = .006) in children and 36 min ( p = .022) in adolescents with URLi compared with Humalog. The maximum and overall exposure were similar between treatments. Postprandial glucose at 1 h was reduced by 42 mg/dl in children ( p = .008), 19 mg/dl ( p = .195) in adolescents and 34 mg/dl ( p = .018) in adults following URLi versus Humalog. The glucose excursion during a 5‐h test meal period was reduced by 16% in children and 9% in adolescents compared with Humalog. URLi was well tolerated in all age groups. Conclusions: URLi showed an accelerated insulin lispro absorption and greater postprandial glucose reduction compared with Humalog in children, adolescents and adults with T1D.
- Open Access
- 27 May 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (11) , 1423-1434
Ultra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
Background and Objective Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog® in healthy subjects and patients with type 1 or type 2 diabetes mellitus. Methods The analysis included four randomized, double-blind, crossover, single-dose studies (healthy subjects [n = 74], patients with type 1 diabetes [n = 78], and type 2 diabetes [n = 38]) evaluating subcutaneous doses of 7, 15, or 30 U of URLi and Humalog during an 8- to 10-h euglycemic clamp procedure. Results The pooled analysis showed an ~ 5-min faster onset of appearance, an ~8-fold greater exposure in the first 15 min, a 43% reduction in exposure beyond 3 h, and a 68-min shorter exposure duration with URLi vs Humalog across all study populations and dose range. Compared with Humalog, URLi had a 10-min faster onset of action, a 3-fold greater insulin action in the first 30 min, a 35% reduction in insulin action beyond 4 h, and a 44-min shorter duration of action across all populations and dose range. Overall exposure and insulin action were similar between URLi and Humalog for each dose level and study population. Conclusions Across the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range. Clinical Trial Registration NCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017).
- 27 May 2021
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 60 (11) , 1423-1434
Open AccessUltra Rapid Lispro (URLi) Accelerates Insulin Lispro Absorption and Insulin Action vs Humalog® Consistently Across Study Populations: A Pooled Analysis of Pharmacokinetic and Glucodynamic Data
Background and Objective Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This pooled analysis compared the pharmacokinetics and glucodynamics between URLi and Humalog® in healthy subjects and patients with type 1 or type 2 diabetes mellitus. Methods The analysis included four randomized, double-blind, crossover, single-dose studies (healthy subjects [n = 74], patients with type 1 diabetes [n = 78], and type 2 diabetes [n = 38]) evaluating subcutaneous doses of 7, 15, or 30 U of URLi and Humalog during an 8- to 10-h euglycemic clamp procedure. Results The pooled analysis showed an ~ 5-min faster onset of appearance, an ~8-fold greater exposure in the first 15 min, a 43% reduction in exposure beyond 3 h, and a 68-min shorter exposure duration with URLi vs Humalog across all study populations and dose range. Compared with Humalog, URLi had a 10-min faster onset of action, a 3-fold greater insulin action in the first 30 min, a 35% reduction in insulin action beyond 4 h, and a 44-min shorter duration of action across all populations and dose range. Overall exposure and insulin action were similar between URLi and Humalog for each dose level and study population. Conclusions Across the studied populations and dose range, URLi consistently demonstrated a faster absorption, reduced late exposure, and overall shorter exposure duration compared with Humalog. Similarly, URLi demonstrated earlier insulin action while reducing late insulin action and shorter insulin action compared with Humalog across the study populations and dose range. Clinical Trial Registration NCT02942654 (registered: 21 October, 2016), NCT03286751 (registered: 15 September, 2017), NCT03166124 (registered: 23 May, 2017), and NCT03305822 (registered: 5 October, 2017).
- Open Access
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1762-1777.e4
Pharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects
- 1 September 2020
- Published by Elsevier in Clinical Therapeutics
- Vol. 42 (9) , 1762-1777.e4
Open AccessPharmacokinetic and Glucodynamic Responses of Ultra Rapid Lispro vs Lispro Across a Clinically Relevant Range of Subcutaneous Doses in Healthy Subjects
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)
URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups. In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D. Disclosure R. Aronson: None. H. Linnebjerg: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. J. Leohr: None. E.S. LaBell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company, Johnson & Johnson, Novartis AG. D.E. Coutant: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Eli Lilly and Company. Q. Zhang: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. T. Danne: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Sanofi. R.K. Pollom: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. Funding Eli Lilly and Company
- 1 June 2020
- Published by American Diabetes Association in Diabetes
- Vol. 69 (Supplement)
1018-P: Ultra-Rapid Lispro (URLi) Showed Greater Reduction in Postprandial Glucose (PPG) vs. Humalog in Children, Adolescents, and Adult Patients with Type 1 Diabetes (T1D)
URLi is a novel insulin lispro formulation that was developed to more closely match physiological insulin secretion. This 2-site, randomized, 2-period crossover, double-blind study evaluated the pharmacokinetics and glucodynamics during a liquid test meal, after a single 0.2 U/kg SC dose of URLi or Humalog in 13 children, 14 adolescents, 15 adults with T1D. Onset of insulin appearance was faster with URLi vs. Humalog in children (1.1 vs. 6.5 min; p=0.0002), adolescents (1.9 vs. 6.4 min; p=0.001), and adults (0.9 vs. 4.8 min; p=0.004). Early exposure (AUC0-15min) was greater with URLi vs. Humalog: 7-fold (p3-7h) was reduced by 58% (p<0.0001) in children, 40% (p=0.013) in adolescents, 37% (p=0.021) in adults. Total exposure was similar in URLi and Humalog. At 1h, URLi reduced PPG by 42 mg/dL (p=0.008) in children, 19 mg/dL (p=0.195) in adolescents, 34 mg/dL (p=0.018) in adults, vs. Humalog. At 2h, URLi reduced the PPG by 32 mg/dL (p=0.11) in children, 39 mg/dL (p=0.051) in adolescents and was not statistically different in adults, vs. Humalog. URLi was well tolerated in all age groups. In summary, URLi accelerated insulin lispro absorption, reduced late exposure and early PPG following a test meal vs. Humalog in children, adolescents, and adults with T1D. Disclosure R. Aronson: None. H. Linnebjerg: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. J. Leohr: None. E.S. LaBell: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company, Johnson & Johnson, Novartis AG. D.E. Coutant: Employee; Self; Eli Lilly and Company. Employee; Spouse/Partner; Eli Lilly and Company. Q. Zhang: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. T. Danne: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Eli Lilly and Company, Medtronic, Novo Nordisk A/S, Sanofi. R.K. Pollom: Employee; Self; Eli Lilly and Company. Stock/Shareholder; Self; Eli Lilly and Company. Funding Eli Lilly and Company
- Open Access
- 29 May 2020
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (12) , 1589-1599
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
Background Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetics, glucodynamics, safety, and tolerability of URLi and Humalog® in patients with type 1 diabetes mellitus (T1DM). Methods This was a phase I, two-period, randomised, double-blind, crossover glucose clamp study in younger adult (aged 18–45 years; n = 41) and elderly (aged ≥65 years; n = 39) patients with T1DM. At each dosing visit, patients received either URLi or Humalog (15 units subcutaneously) followed by a 10 h automated euglycaemic clamp procedure. Serum insulin lispro and blood glucose were measured. Results Insulin lispro appeared in serum 6 min faster, and exposure was 7.2-fold greater over the first 15 min postdose with URLi versus Humalog in both age groups. Exposure beyond 3 h postdose was 39–41% lower, and exposure duration was reduced by 72–74 min with URLi versus Humalog in both age groups. Onset of insulin action was 11–12 min faster, and insulin action was 3-fold greater over the first 30 min postdose with URLi versus Humalog in both age groups. Insulin action beyond 4 h postdose was 44–54% lower, and duration of action was reduced by 34–44 min with URLi versus Humalog in both age groups. Overall exposure and total insulin action remained similar for both treatments. URLi and Humalog were well tolerated. Conclusion In patients with T1DM, URLi showed ultra-rapid pharmacokinetics and glucodynamics, with the differences between URLi and Humalog in elderly patients mirroring those in younger adults. ClinicalTrials.gov identifier: NCT03166124.
- 29 May 2020
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 59 (12) , 1589-1599
Open AccessPharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
Background Ultra rapid lispro (URLi) is a novel insulin lispro formulation developed to more closely match physiological insulin secretion and improve postprandial glucose control. This study compared the pharmacokinetics, glucodynamics, safety, and tolerability of URLi and Humalog® in patients with type 1 diabetes mellitus (T1DM). Methods This was a phase I, two-period, randomised, double-blind, crossover glucose clamp study in younger adult (aged 18–45 years; n = 41) and elderly (aged ≥65 years; n = 39) patients with T1DM. At each dosing visit, patients received either URLi or Humalog (15 units subcutaneously) followed by a 10 h automated euglycaemic clamp procedure. Serum insulin lispro and blood glucose were measured. Results Insulin lispro appeared in serum 6 min faster, and exposure was 7.2-fold greater over the first 15 min postdose with URLi versus Humalog in both age groups. Exposure beyond 3 h postdose was 39–41% lower, and exposure duration was reduced by 72–74 min with URLi versus Humalog in both age groups. Onset of insulin action was 11–12 min faster, and insulin action was 3-fold greater over the first 30 min postdose with URLi versus Humalog in both age groups. Insulin action beyond 4 h postdose was 44–54% lower, and duration of action was reduced by 34–44 min with URLi versus Humalog in both age groups. Overall exposure and total insulin action remained similar for both treatments. URLi and Humalog were well tolerated. Conclusion In patients with T1DM, URLi showed ultra-rapid pharmacokinetics and glucodynamics, with the differences between URLi and Humalog in elderly patients mirroring those in younger adults. ClinicalTrials.gov identifier: NCT03166124.
- Open Access
- 21 May 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (10) , 1789-1798
Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
Aims: To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (Novo Nordisk), in patients with type 1 diabetes (T1D). Materials and Methods: This was a randomized, double‐blind, four‐period, crossover study, conducted in 68 patients with T1D. Patients received the same individualized subcutaneous dose of each study drug immediately prior to a liquid test meal. For comparison, 12 healthy subjects received the same test meal. Results: URLi had a significantly faster insulin absorption compared to the other insulins tested. Early half‐maximal drug concentration was reached 13 minutes after administration of URLi, which was 6 minutes faster than Fiasp, 13 minutes faster than Humalog, and 14 minutes faster than NovoRapid (all P <0.0001). Early insulin exposure was significantly greater and late insulin exposure was reduced after URLi compared to the other insulins. URLi achieved the greatest numerical reduction in postprandial glucose (PPG) at 2 hours post‐meal (7 mg/dL vs Fiasp) and was significantly different from Humalog (21 mg/dL) and Novo Rapid (29 mg/dL). Additionally, glucose excursions over the first 3 hours post‐meal with URLi were comparable to those in healthy subjects. Conclusions: URLi demonstrated the fastest insulin absorption and the greatest numeric PPG‐lowering effect compared to the other insulins tested. URLi more closely matched the early physiological glucose control observed in healthy subjects.
- 21 May 2020
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 22 (10) , 1789-1798
Open AccessUltra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study
Aims: To compare the pharmacokinetic (PK) and glucodynamic (GD) characteristics of ultra rapid lispro (URLi; Eli Lilly and Company, Indianapolis, Indiana), Fiasp® (Novo Nordisk, Bagsvaerd, Denmark), Humalog® (Eli Lilly and Company) and NovoRapid® (Novo Nordisk), in patients with type 1 diabetes (T1D). Materials and Methods: This was a randomized, double‐blind, four‐period, crossover study, conducted in 68 patients with T1D. Patients received the same individualized subcutaneous dose of each study drug immediately prior to a liquid test meal. For comparison, 12 healthy subjects received the same test meal. Results: URLi had a significantly faster insulin absorption compared to the other insulins tested. Early half‐maximal drug concentration was reached 13 minutes after administration of URLi, which was 6 minutes faster than Fiasp, 13 minutes faster than Humalog, and 14 minutes faster than NovoRapid (all P <0.0001). Early insulin exposure was significantly greater and late insulin exposure was reduced after URLi compared to the other insulins. URLi achieved the greatest numerical reduction in postprandial glucose (PPG) at 2 hours post‐meal (7 mg/dL vs Fiasp) and was significantly different from Humalog (21 mg/dL) and Novo Rapid (29 mg/dL). Additionally, glucose excursions over the first 3 hours post‐meal with URLi were comparable to those in healthy subjects. Conclusions: URLi demonstrated the fastest insulin absorption and the greatest numeric PPG‐lowering effect compared to the other insulins tested. URLi more closely matched the early physiological glucose control observed in healthy subjects.
- 4 February 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (5) , 1193-1201
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus
Aims: When treated with basal insulin peglispro (BIL), patients with type 1 diabetes mellitus (T1DM) exhibit weight loss and lower prandial insulin requirements versus insulin glargine (GL), while total insulin requirements remain similar. One possible explanation is enhanced lipid oxidation and improved ability to switch between glucose and lipid metabolism with BIL. This study compared the effects of BIL and GL on glucose and lipid metabolism in subjects with T1DM. Materials and Methods: Fifteen subjects with T1DM were enrolled into this open‐label, randomised, crossover study, and received once‐daily stable, individualised, subcutaneous doses of BIL and GL for 4 weeks each. Respiratory quotient (RQ) was measured using whole‐room calorimetry, and energy expenditure (EE) and concentrations of ketone bodies (3‐hydroxybutyrate) and acylcarnitines were assessed. Results: Mean sleep RQ was lower during the BIL (0.822) than the GL (0.846) treatment period, indicating greater lipid metabolism during the post‐absorptive period with BIL. Increases in carbohydrate oxidation following breakfast were greater during BIL than GL treatment (mean change in RQ following breakfast 0.111 for BIL, 0.063 for GL). Furthermore, BIL treatment increased total daily EE versus GL (2215.9 kcal/d for BIL, 2135.5 kcal/d for GL). Concentrations of ketone bodies and acylcarnitines appeared to be higher following BIL than GL treatment. Conclusions: BIL increased sleeping fat oxidation, EE, ketone bodies, acylcarnitines and post‐prandial glucose metabolism when switching from conventional insulin, thus, restoring metabolic flexibility and increasing thermogenesis. These changes may explain the previously observed weight loss with BIL versus GL.
- 4 February 2018
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (5) , 1193-1201
Basal insulin peglispro increases lipid oxidation, metabolic flexibility, thermogenesis and ketone bodies compared to insulin glargine in subjects with type 1 diabetes mellitus
Aims: When treated with basal insulin peglispro (BIL), patients with type 1 diabetes mellitus (T1DM) exhibit weight loss and lower prandial insulin requirements versus insulin glargine (GL), while total insulin requirements remain similar. One possible explanation is enhanced lipid oxidation and improved ability to switch between glucose and lipid metabolism with BIL. This study compared the effects of BIL and GL on glucose and lipid metabolism in subjects with T1DM. Materials and Methods: Fifteen subjects with T1DM were enrolled into this open‐label, randomised, crossover study, and received once‐daily stable, individualised, subcutaneous doses of BIL and GL for 4 weeks each. Respiratory quotient (RQ) was measured using whole‐room calorimetry, and energy expenditure (EE) and concentrations of ketone bodies (3‐hydroxybutyrate) and acylcarnitines were assessed. Results: Mean sleep RQ was lower during the BIL (0.822) than the GL (0.846) treatment period, indicating greater lipid metabolism during the post‐absorptive period with BIL. Increases in carbohydrate oxidation following breakfast were greater during BIL than GL treatment (mean change in RQ following breakfast 0.111 for BIL, 0.063 for GL). Furthermore, BIL treatment increased total daily EE versus GL (2215.9 kcal/d for BIL, 2135.5 kcal/d for GL). Concentrations of ketone bodies and acylcarnitines appeared to be higher following BIL than GL treatment. Conclusions: BIL increased sleeping fat oxidation, EE, ketone bodies, acylcarnitines and post‐prandial glucose metabolism when switching from conventional insulin, thus, restoring metabolic flexibility and increasing thermogenesis. These changes may explain the previously observed weight loss with BIL versus GL.
- 10 October 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (2) , 419-426
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes
Aims: To test the hypothesis that, as well as lowering weight and increasing plasma triglyceride (TG) levels and hepatic fat compared with insulin glargine (GL) in patients with type 1 diabetes, the attenuated peripheral effects of basal insulin peglispro (BIL) may include increased free fatty acid flux to the liver, causing increased very‐low‐density lipoprotein (VLDL)‐TG secretion and lipid oxidation, and decreased TG adipose tissue deposition. Methods: In this open‐label, randomized, 2‐period crossover study, 14 patients with type 1 diabetes received once‐daily, individualized, stable BIL or GL doses for 3 weeks. Palmitate flux was assessed using [9,10‐ 3 H]palmitate infusion. VLDL‐TG secretion, clearance and oxidation rate were assessed using primed‐constant infusion of ex vivo labelled [1‐ 14 C]VLDL‐TG, while VLDL‐TG storage rate was assessed using [9,10‐ 3 H]VLDL‐TG bolus injection. Results: The VLDL‐TG concentration and secretion rate, and palmitate flux were statistically significantly higher during BIL than during GL treatment (58%, 51% and 35%, respectively). The ratios of least squares (LS) geometric means for VLDL‐TG clearance and oxidation were 0.92 (95% confidence interval [CI] 0.72, 1.17) and 1.31 (95% CI 0.91, 1.90), respectively. The difference in LS means for VLDL‐TG storage rate was −0.36 (95% CI −0.83, 0.12). Conclusions: BIL‐treated patients had higher effective lipolysis, VLDL‐TG secretion and VLDL‐TG concentration compared with GL‐treated patients, explaining the increased plasma TG concentrations reported previously. Data support attenuated effects of BIL on lipolysis, in addition to the recently described hepato‐preferential glucodynamic effects.
- 10 October 2017
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 20 (2) , 419-426
Attenuated suppression of lipolysis explains the increases in triglyceride secretion and concentration associated with basal insulin peglispro relative to insulin glargine treatment in patients with type 1 diabetes
Aims: To test the hypothesis that, as well as lowering weight and increasing plasma triglyceride (TG) levels and hepatic fat compared with insulin glargine (GL) in patients with type 1 diabetes, the attenuated peripheral effects of basal insulin peglispro (BIL) may include increased free fatty acid flux to the liver, causing increased very‐low‐density lipoprotein (VLDL)‐TG secretion and lipid oxidation, and decreased TG adipose tissue deposition. Methods: In this open‐label, randomized, 2‐period crossover study, 14 patients with type 1 diabetes received once‐daily, individualized, stable BIL or GL doses for 3 weeks. Palmitate flux was assessed using [9,10‐ 3 H]palmitate infusion. VLDL‐TG secretion, clearance and oxidation rate were assessed using primed‐constant infusion of ex vivo labelled [1‐ 14 C]VLDL‐TG, while VLDL‐TG storage rate was assessed using [9,10‐ 3 H]VLDL‐TG bolus injection. Results: The VLDL‐TG concentration and secretion rate, and palmitate flux were statistically significantly higher during BIL than during GL treatment (58%, 51% and 35%, respectively). The ratios of least squares (LS) geometric means for VLDL‐TG clearance and oxidation were 0.92 (95% confidence interval [CI] 0.72, 1.17) and 1.31 (95% CI 0.91, 1.90), respectively. The difference in LS means for VLDL‐TG storage rate was −0.36 (95% CI −0.83, 0.12). Conclusions: BIL‐treated patients had higher effective lipolysis, VLDL‐TG secretion and VLDL‐TG concentration compared with GL‐treated patients, explaining the increased plasma TG concentrations reported previously. Data support attenuated effects of BIL on lipolysis, in addition to the recently described hepato‐preferential glucodynamic effects.
- 21 September 2017
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 6 (6) , 556-563
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products with identical amino acid sequences. This was a phase 1 single‐site, randomized, subject‐ and investigator‐blinded, 4‐treatment, 4‐period crossover study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of LY IGlar and IGlar at 2 different doses. Fasted healthy subjects were randomly assigned to receive 2 single doses of LY IGlar and IGlar (0.3 and 0.6 U/kg for each product). Blood samples were collected up to 24 hours postdose to assess PK, and a euglycemic clamp lasting up to 24 hours postdose was conducted to assess PD. Twenty‐four healthy subjects aged 23 to 52 years participated in the study. The primary PK parameters (area under the concentration versus time curve from 0 to 24 hours [AUC0–24] and maximum observed drug concentration [Cmax]) and PD parameters (total amount of glucose infused during the clamp [Gtot] and maximum glucose infusion rate [Rmax]) were not statistically different between LY IGlar and IGlar at either dose. No safety concerns were noted with either drug. The study demonstrated that the PK and PD parameters for LY IGlar and IGlar were comparable following single doses at both 0.3 and 0.6 U/kg.
- 21 September 2017
- Published by Wiley in Clinical Pharmacology in Drug Development
- Vol. 6 (6) , 556-563
LY2963016 Insulin Glargine and Insulin Glargine (Lantus) Produce Comparable Pharmacokinetics and Pharmacodynamics at Two Dose Levels
LY2963016 (LY IGlar) and Lantus (IGlar) are insulin glargine products with identical amino acid sequences. This was a phase 1 single‐site, randomized, subject‐ and investigator‐blinded, 4‐treatment, 4‐period crossover study to compare the pharmacokinetic (PK) and pharmacodynamic (PD) properties of LY IGlar and IGlar at 2 different doses. Fasted healthy subjects were randomly assigned to receive 2 single doses of LY IGlar and IGlar (0.3 and 0.6 U/kg for each product). Blood samples were collected up to 24 hours postdose to assess PK, and a euglycemic clamp lasting up to 24 hours postdose was conducted to assess PD. Twenty‐four healthy subjects aged 23 to 52 years participated in the study. The primary PK parameters (area under the concentration versus time curve from 0 to 24 hours [AUC0–24] and maximum observed drug concentration [Cmax]) and PD parameters (total amount of glucose infused during the clamp [Gtot] and maximum glucose infusion rate [Rmax]) were not statistically different between LY IGlar and IGlar at either dose. No safety concerns were noted with either drug. The study demonstrated that the PK and PD parameters for LY IGlar and IGlar were comparable following single doses at both 0.3 and 0.6 U/kg.